Although the optimal dosing of an antipsychotic medication is known to be essential
in the long-term management of schizophrenia, in case of novel drugs such as cariprazine,
determining the right dosing strategy is not that simple. Without decades of experience
with a particular compound, evidence regarding dosing and titration comes primarily
from double-blind, placebo controlled clinical trials that are not necessarily mirroring
the real-life experiences of doctors. Via summarizing data from both clinical data
(n = 3275) and real-world evidence (observational study n = 116, case studies n =
29), this perspective paper aims to shed a light on the appropriate dosing strategies
of cariprazine from treatment initiation through switching strategies to concomitant
medications.
